UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed solid tumor or lymphoma
• •* Progressive disease after standard therapy
• •* No other therapy is likely to improve survival
• •Prostate cancer patients must have progressed through hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists and withdrawal of testosterone receptor antagonists
• •* Patients must continue on GnRH agonist during study (if orchiectomy has not been performed) and have castrate testosterone levels
• •Brain metastases allowed if treated and the patient has been stable off anti-seizure medication or steroids for \> 6 months
• •No local complications from disease requiring urgent therapy (i.e., hydronephrosis, spinal cord compression, or severe pain requiring improved pain management)
• •PATIENT CHARACTERISTICS:
• •Age
• •18 and over
• •Performance status
• •ECOG 0-2
• •Life expectancy
• •At least 3 months
• •Hematopoietic
• •Absolute neutrophil count greater than 1,000/mm\^3
• •Platelet count greater than 100,000/mm\^3
• •12-hour fasting glucose no greater than 110 mg/dL OR
• •12-hour fasting glucose no greater than 140 mg/dL with hemoglobin A1C no greater than 6.5 mg/dL
• •Hepatic
• •PT/PTT no greater than 1.5 times upper limit of normal (ULN)
• •Bilirubin no greater than 1.5 times ULN (unless Gilbert's syndrome present)
• •AST/ALT no greater than 2.5 times ULN
• •Renal
• •Creatinine clearance greater than 60 mL/min OR
• •Creatinine no greater than 1.5 mg/dL
• •Cardiovascular
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •Pulmonary
• •No interstitial lung disease within the past year
• •No requirement for oxygen therapy for hypoxia in the past 6 months
• •Gastrointestinal
• •No diagnosis of duodenal or gastric ulcer
• •No severe gastritis within the past 6 months
• •Other
• •HIV negative
• •No prior allergic reactions to other indolocarbazoles
• •No diabetes or hyperglycemia within the past year that required a diabetic diet, oral hypoglycemics, or insulin
• •No other uncontrolled illness
• •No active infection
• •No seizure disorder
• •No psychiatric illness that would preclude study compliance
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 2 months after study therapy
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• •No prior UCN-01
• •Endocrine therapy
• •See Disease Characteristics
• •No other concurrent oral or IV steroids
• •Radiotherapy
• •At least 4 weeks since prior radiotherapy and recovered
• •Surgery
• •See Disease Characteristics
• •At least 21 days since prior major surgery
• •Other
• •See Disease Characteristics
• •At least 4 weeks since prior investigational agents
• •No other concurrent anticancer therapy